What is the easiest way to handle the discontinuation of Pitobrutinib/Pitobrutinib? Experts are here to help!

Pirtobrutinib/Pirtobrutinib As a new generation of non-covalent, reversible Bruton's tyrosine kinase (BTK) inhibitor, its discontinuation management is more flexible than traditional BTK inhibitors such as ibrutinib or acalabrutinib. Since the binding of pitobrutinib to the BTK target is non-covalent, the half-life of the drug is short (about 20 hours). Once the drug is discontinued, its concentration in the body decreases rapidly and the inhibitory effect on BTK disappears quickly. Therefore, if the drug needs to be discontinued, there is no need to carry out complicated "tapering" or "substitution transition". Instead, the drug can be stopped directly, but it must be done under the guidance of a doctor, and the disease progression and changes in adverse reactions must be closely monitored.

In actual clinical operations, if a patient needs to suspend medication due to mild or reversible adverse reactions (such as fatigue, mild diarrhea, rash, etc.), the strategy of "shortly discontinuing medication and resuming after symptom improvement" can be adopted. It is usually recommended to stop taking the drug for a few days to a week, and then resume taking the drug at the original dose after the symptoms of discomfort subside. For more serious adverse reactions, such as grade 3 or above hematological toxicity (such as severe neutropenia), infection or abnormal heart rhythm, longer discontinuation of treatment may be required, together with symptomatic and supportive treatment. After symptoms are relieved, the patient can decide whether to resume at a lower dose or switch to other targeted regimens based on individual patient tolerance.

If the patient has to permanently discontinue the drug due to disease progression or uncontrollable toxic reactions, doctors will evaluate the next treatment plan based on the condition, such as switching to other types of targeted drugs, immunotherapy or chemotherapy. It should be noted that pitobrutinib has shown a high response rate in indications such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Before stopping the drug, special attention should be paid to disease indicators such as blood images, enlarged lymph nodes, bone marrow status, etc., to prevent rapid rebound of the disease.

Reference materials:https://go.drugbank.com/drugs/DB17472